EXPERIENCE OF INTRAVENOUS INJECTION OF NORMAL HUMAN IMMUNOGLOBULIN IN A PATIENT WITH KAWASAKI SYNDROME
https://doi.org/10.15690/pf.v11i4.1072
Abstract
The article presents a case of late diagnosis of cutaneomucosal lymphonodular syndrome (Kawasaki syndrome). The child featured fever, mucosal lesion (conjunctivitis, stomatitis), rash, thick edemas on arms and feet, arthritis and coronaritis. Initial therapy proved ineffective. Pathogenetic therapy, which proved to be rather effective, was prescribed after diagnosis was confirmed. The authors present a case of successful use of normal human immunoglobulin for intravenous injections in the dose of 2 g/kg of body weight per course in combination with acetylsalicylic acid in the dose of 80 mg/kg per day. Body temperature decreased down to subfebrile figures and foot pain attenuated as early as after 1 day of treatment. Fever, rash, stomatitis and conjunctivitis terminated, edemas of limbs and arthritic manifestations attenuated considerably and laboratory parameters of disease activity normalized after 1 week (ESR and CRP). Inflammation of coronary arteries terminated after 3 weeks. No adverse events in the setting of immunoglobulin therapy were observed.
About the Authors
T. V. Sleptsova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
R. V. Denisova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
K. B Isaeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. G. Chistyakova
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
A. N. Fetisova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
O. L. Lomakina
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Newburger J.W., Takahashi M., Gerber M.A. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004; 114: 1708−33.
2. Baranov A.A., Alekseeva E.I., Gaedicke G. Paediatric Rheumatology. Atlas. Reed Elsevier LLC (Russia). 2011.
3. JCS Joint Working Group. Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease 2008. Circ J. 2010; 74: 1989–2020.
4. Cassidy J., Petty R. Texbook of paediatric rheumatology, 6th еd. Elsevier Saunders. 2010.
5. Ozen S., Ruperto N., Dillon M.J. et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006; 65: 936–41.
6. Lyskina G.A., Shirinskaya O.G. Slizisto-kozhnyi limfonodulyarnyi sindrom (sindrom Kavasaki). Diagnostika i lechenie [Lymphonodular mucocutaneous syndrome (Kawasaki syndrome). Diagnosis and treatment]. Moscow, Vidar-M, 2008.
7. Oates-Whitehead R.M., Baumer J.H., Haines L. et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003. CD004000.
8. Weng K.-P., Hsieh K.-S., Huan S.-H., Ou S.-F., Ma C.-Y., Ho T.-Y., Lai C.-R., Ger L.-P. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease. Kaohsiung JournaI of Medical Sciences. 2012; 28: 23−29.
9. Provan D., Nokes T.J.C., Agrawal S., Winer J.B., Wood P. Clinical guidelines for the use of intravenous immunoglobulin. Department of Health, London. 2007.
10. Newberger, J.W., Takahashi, M., Beiser, A.S. et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki Syndrome. N Engl J Med. 1991; 324 (23): 1633−1639.
11. Sakata K., Hamaoka K., Ozawa S.-I., Niboshi A., Yoshihara T., Nishiki T., Nakagawa Y., Kazuta K., Morimoto Y., Kamiya Y., Yamamoto T., Horii Y., Kido S. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur J Pediatr. 2007; 166: 565–571.
Review
For citations:
Sleptsova T.V., Alexeeva E.I., Bzarova T.M., Denisova R.V., Isaeva K.B., Chistyakova E.G., Fetisova A.N., Lomakina O.L. EXPERIENCE OF INTRAVENOUS INJECTION OF NORMAL HUMAN IMMUNOGLOBULIN IN A PATIENT WITH KAWASAKI SYNDROME. Pediatric pharmacology. 2014;11(4):97-102. (In Russ.) https://doi.org/10.15690/pf.v11i4.1072
Views:
13490
Email this article 